Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Biotech firm backs controversial CRISPR challenger

Nature volume 541, page 447 (2017)Cite this article

Subjects

This article has been updated

What Novozymes might do with the NgAgo protein, claimed by some to be a powerful gene editor, is still unclear.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 23 January 2017

    An earlier version of this story said that Jin-Soo Kim had written a report showing NgAgo’s use as a gene silencer; in fact, the report only raises this possibility. Kim’s affiliation was also missing.

References

  1. Gao, F. et al. Nature Biotechnol. 34, 768–773 (2016).

    Article  CAS  Google Scholar 

  2. Lee, S. H. et al. Nature Biotechnol. http://dx.doi.org/10.1038/nbt.3753 (2016).

  3. Ye, S. et al. Preprint at BioRxiv http://dx.doi.org/10.1101/101923 (2017).

Download references

Authors
  1. David Cyranoski
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Updated: NgAgo gene-editing controversy escalates in peer-reviewed papers 2016-Nov-23

Beyond CRISPR: A guide to the many other ways to edit a genome 2016-Aug-08

Replications, ridicule and a recluse: the controversy over NgAgo gene-editing intensifies 2016-Aug-08

Related external links

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cyranoski, D. Biotech firm backs controversial CRISPR challenger. Nature 541, 447 (2017). https://doi.org/10.1038/nature.2017.21343

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature.2017.21343

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research